Literature DB >> 30054182

A 7-year observation of the effect of subthalamic deep brain stimulation on impulse control disorder in patients with Parkinson's disease.

Aryun Kim1, Young Eun Kim2, Han-Joon Kim1, Ji Young Yun3, Hui-Jun Yang4, Woong-Woo Lee5, Chae Won Shin6, Hyeyoung Park7, Yu Jin Jung8, Ahro Kim9, Gwanhee Ehm10, Yoon Kim1, Mihee Jang11, Beomseok Jeon12.   

Abstract

INTRODUCTION: Previous studies have reported improvement of impulse control disorders (ICDs) after subthalamic nucleus (STN) deep brain stimulation (DBS) as well as some de novo ICDs. However, it is not clear how STN DBS changes ICDs in the long-term. METHODS MATERIALS: Eighty-nine patients with Parkinson's disease (PD) who had received a bilateral STN DBS from 2005 to 2009 and were included in our previous study were followed for 7 years with the modified Minnesota Impulsive Disorders Interview (mMIDI). Their mMIDI scores, medication, and frontal function tests measured preoperatively and at 1 and 7 years postoperatively were compared.
RESULTS: A total of 61 patients were analyzed after excluding 10 and 18 patients due to death and lost to follow-up, respectively. The numbers of the patients with an ICD at each point were 8, 10, and 7, respectively. All preoperative ICDs disappeared after DBS. De novo ICDs within 1 year after DBS disappeared except for 1 patient. Six of the seven patients, who reported ICDs 7 years after the DBS developed that ICD between 1 and 7 years. Their total levodopa equivalent daily dose (LEDD) and dopamine agonist dose were not higher compared to the other 54 patients without ICDs. There was no correlation with the frontal lobe dysfunction and the electrode position in the subthalamus.
CONCLUSION: STN DBS improves baseline ICDs and results in the development of "transient" de novo ICDs in the short-term. In addition, there is a unique group of the patients who develop ICDs a long time after DBS.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Deep brain stimulation; Impulse control disorders; Parkinson's disease; Subthalamus

Mesh:

Year:  2018        PMID: 30054182     DOI: 10.1016/j.parkreldis.2018.07.010

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  6 in total

1.  Adaptive deep brain stimulation as advanced Parkinson's disease treatment (ADAPT study): protocol for a pseudo-randomised clinical study.

Authors:  Dan Piña-Fuentes; Martijn Beudel; Simon Little; Peter Brown; D L Marinus Oterdoom; J Marc C van Dijk
Journal:  BMJ Open       Date:  2019-06-14       Impact factor: 2.692

Review 2.  Medications, Deep Brain Stimulation, and Other Factors Influencing Impulse Control Disorders in Parkinson's Disease.

Authors:  Robert S Eisinger; Adolfo Ramirez-Zamora; Samuel Carbunaru; Brandon Ptak; Zhongxing Peng-Chen; Michael S Okun; Aysegul Gunduz
Journal:  Front Neurol       Date:  2019-02-26       Impact factor: 4.003

Review 3.  Impulse Control Disorders in Parkinson's Disease: From Bench to Bedside.

Authors:  Andrea Augustine; Catharine A Winstanley; Vaishnav Krishnan
Journal:  Front Neurosci       Date:  2021-03-12       Impact factor: 4.677

Review 4.  Psychiatric Manifestation in Patients with Parkinson's Disease.

Authors:  Ji Won Han; Yebin D Ahn; Won-Seok Kim; Cheol Min Shin; Seong Jin Jeong; Yoo Sung Song; Yun Jung Bae; Jong-Min Kim
Journal:  J Korean Med Sci       Date:  2018-11-01       Impact factor: 2.153

5.  Impulse Control Disorders in Parkinson's Disease. A Brief and Comprehensive Review.

Authors:  Emilia M Gatto; Victoria Aldinio
Journal:  Front Neurol       Date:  2019-04-17       Impact factor: 4.003

6.  Eight-year follow-up outcome of subthalamic deep brain stimulation for Parkinson's disease: Maintenance of therapeutic efficacy with a relatively low levodopa dosage and stimulation intensity.

Authors:  Lulu Jiang; Wanru Chen; Qiyu Guo; Chao Yang; Jing Gu; Wenbiao Xian; Yanmei Liu; Yifan Zheng; Jing Ye; Shaohua Xu; Yu Hu; Lei Wu; Jie Chen; Hao Qian; Xiaoli Fu; Jinlong Liu; Ling Chen
Journal:  CNS Neurosci Ther       Date:  2021-08-05       Impact factor: 5.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.